Biopharmaceutical News and Research

RSS

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

ACC’s initiative can help cardiologists address critical patient needs, deliver high-quality care

The American College of Cardiology's ongoing COVID-19 response initiative is welcoming support from the Boehringer Ingelheim and Eli Lilly and Company Alliance to continue providing real-time clinical guidance on COVID-19.

18 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020

Validation of AI tools for cancer immunotherapy may be a step closer

For Artificial Intelligence (AI) tools being developed at Case Western Reserve University to have impact in the fight against cancer, they're going to have to be validated in rigorous human clinical trials.

10 Sep 2020

Optibrium’s peer-reviewed study highlights the value of deep learning to impute drug discovery data

Optibrium, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling.

10 Sep 2020

Insilico Medicine launches new system for COVID-19 basic and clinical research

Today Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, announced the launch of a new system for COVID-19 basic and clinical research.

9 Sep 2020

AstraZeneca COVID-19 vaccine trial paused due to suspected adverse reaction

The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).

8 Sep 2020

Nasal sprays are a known remedy for preventing opioid overdose deaths

Between 250 and 270 people die each year from heroin or opioid overdoses in Norway. In the EU, thousands die. European users now have a better option available for helping each other.

3 Sep 2020

New method offers hope to patients in critical need of kidney transplant

Kidneys from deceased donors with hepatitis C virus (HCV) infection can be safely transplanted into noninfected recipients when a regimen of direct-acting antiviral therapies is initiated as early as two days after the transplant, according to a study from Massachusetts General Hospital (MGH).

2 Sep 2020

New breast cancer drug is safe and effective, can halt disease progression

A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy.

28 Aug 2020

Preclinical studies of a COVID-19 vaccine candidate show positive results

Preclinical studies of a COVID-19 vaccine candidate at the University of Alabama at Birmingham show positive results that appear to distinguish this vaccine candidate from other vaccine candidates that are currently in advanced stages of clinical development, the Maryland-based Altimmune Inc. announced today.

25 Aug 2020

Study examines potential therapeutic approach for Alzheimer's disease

Research looking at a possible new therapeutic approach for Alzheimer's disease was recently published in the Journal of Neuroinflammation.

25 Aug 2020

AI can expedite drug repurposing process for finding COVID-19 therapies, says GlobalData

Out of all the different approaches available to find new therapies to treat COVID-19, drug repurposing is one of the fastest and safest methods, as the drugs are already being used to treat other conditions therefore leading to fewer chances of adverse reactions.

21 Aug 2020

Using engineered off-the-shelf therapeutic T cells to fight cancer

Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in 'teaching' the body's immune T cells to recognize and kill specific cancer cells, and human clinical trials have shown that this approach can successfully eliminate tumors.

20 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

Harbour BioMed and Viva Biotech announce strategic collaboration to promote incubation of biotech startups

Harbour BioMed, a global clinical stage biopharmaceutical company and Viva Biotech (Shanghai) Ltd., a world-leading structure-based drug discovery platform today announced a strategic partnership under which both parties will collate their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups.

31 Jul 2020

Investigational drug shows promising results for treating HNSCC tumors

Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas (HNSCC) account for the majority of these cases.

31 Jul 2020

Two young scientists receive Damon Runyon-Sohn Pediatric Cancer Fellowship Award

The Damon Runyon Cancer Research Foundation has named two outstanding young scientists as recipients of the Damon Runyon-Sohn Pediatric Cancer Fellowship Award, committing nearly $500,000 to help address a critical shortage of funding for pediatric cancer research.

30 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale School of Medicine and the biopharmaceutical firm AI Therapeutics have launched a multi-institutional clinical trial of a drug for treating COVID-19.

27 Jul 2020